DE69432315D1 - ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT - Google Patents

ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT

Info

Publication number
DE69432315D1
DE69432315D1 DE69432315T DE69432315T DE69432315D1 DE 69432315 D1 DE69432315 D1 DE 69432315D1 DE 69432315 T DE69432315 T DE 69432315T DE 69432315 T DE69432315 T DE 69432315T DE 69432315 D1 DE69432315 D1 DE 69432315D1
Authority
DE
Germany
Prior art keywords
erbb
antisense nucleic
nucleic acids
plays
role
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432315T
Other languages
English (en)
Other versions
DE69432315T2 (de
Inventor
Wolfgang Brysch
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Georg-F Schlingensiepen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Original Assignee
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH filed Critical Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Publication of DE69432315D1 publication Critical patent/DE69432315D1/de
Application granted granted Critical
Publication of DE69432315T2 publication Critical patent/DE69432315T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DE69432315T 1993-12-23 1994-12-09 ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT Expired - Lifetime DE69432315T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93120710 1993-12-23
EP93120710 1993-12-23
PCT/EP1994/004094 WO1995017507A1 (en) 1993-12-23 1994-12-09 ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE

Publications (2)

Publication Number Publication Date
DE69432315D1 true DE69432315D1 (de) 2003-04-24
DE69432315T2 DE69432315T2 (de) 2004-02-12

Family

ID=8213517

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432315T Expired - Lifetime DE69432315T2 (de) 1993-12-23 1994-12-09 ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT

Country Status (7)

Country Link
US (1) US6365345B1 (de)
EP (1) EP0736093B1 (de)
JP (1) JPH09506770A (de)
AT (1) ATE234919T1 (de)
AU (1) AU1313095A (de)
DE (1) DE69432315T2 (de)
WO (1) WO1995017507A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
HU227190B1 (en) 1999-02-26 2010-10-28 Univ British Columbia Trpm-2 antisense therapy
ATE438411T1 (de) 1999-08-27 2009-08-15 Genentech Inc Dosierung für die behandlung mit anti erbb2- antikörpern
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2404919A1 (en) * 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
US6613567B1 (en) * 2000-09-15 2003-09-02 Isis Pharmaceuticals, Inc. Antisense inhibition of Her-2 expression
KR20100101709A (ko) * 2000-12-01 2010-09-17 리스판스 지네틱스, 인크. 표피 성장 인자 수용체 및 ｈｅｒ2-ｎｅｕ 유전자 발현 및 이들 수준과 생존율의 상관성을 측정하는 방법
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030124513A1 (en) * 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
JP2004536614A (ja) * 2001-08-01 2004-12-09 ユニバーシティ オブ ユタ Ｐｄｅ３環状ヌクレオチド・ホスホジエステラーゼのアイソフォーム選択的な阻害剤および活性化剤
ATE402999T1 (de) * 2002-01-17 2008-08-15 Univ British Columbia Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20060229267A1 (en) * 2004-06-01 2006-10-12 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
PL1814595T3 (pl) * 2004-11-23 2014-08-29 Univ British Columbia Leczenie raka za pomocą kombinacji czynnika zakłócającego ścieżkę sygnalizacyjną EGF oraz oligonukleotydu obniżającego poziom klusteryny
US7247457B2 (en) * 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
EP1957044B1 (de) * 2005-12-01 2013-03-13 Pronai Therapeutics, Inc. Amphotere liposomen
CA2802089A1 (en) 2010-06-11 2011-12-15 Antisense Pharma Gmbh Method for selective oligonucleotide modification
US9427458B2 (en) 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013063A1 (en) 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
WO1993009788A1 (en) 1991-11-13 1993-05-27 Baylor College Of Medicine Triplex forming oligonucleotide reagents targeted to the neu oncogene promoter and method of use
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes

Also Published As

Publication number Publication date
AU1313095A (en) 1995-07-10
WO1995017507A1 (en) 1995-06-29
US6365345B1 (en) 2002-04-02
DE69432315T2 (de) 2004-02-12
EP0736093A1 (de) 1996-10-09
ATE234919T1 (de) 2003-04-15
JPH09506770A (ja) 1997-07-08
EP0736093B1 (de) 2003-03-19

Similar Documents

Publication Publication Date Title
DE69432315D1 (de) ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
ATE194383T1 (de) Antisense oligonukleotide gegen die alpha- regulatorische untereinheit der camp-abhängigen protein-kinase zur behandlung von krebs
PT815218E (pt) Oligonucleotido anti-sentido especificos para vegf humano
DE69613348T2 (de) Hemmung der neovaskulasierung durch vegf-spezifische oligonukleotide
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ATE211393T1 (de) Zusammensetzung die mindestens ein doppel strangiges rna und mindestens ein interferon enthält, zur behandlung von virale hepatitis
ATE232543T1 (de) 11beta-halogen-7alpha-substituierte-estratriene verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha- substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
MA26435A1 (fr) Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.
EP1390472A4 (de) Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
NL300406I1 (nl) Gesubstitueerde dihydrodibenzo (d,f)azepinen, werkwijze ter bereiding ervan, hun toepassing bij het behandelen van enkele verstoringen van het centraal zenuwsysteem, en farmaceutische samenstellingen die ze bevatten
IL147271A0 (en) Compounds that bind her2
ES2170065T3 (es) Modulacion de la proteina quinasa c por oligonucleotidos.
ATE328074T1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
MX9701820A (es) Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE336992T1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen
DE3787437D1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
MX9703188A (es) Acidos nucleicos de aminoacido.
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
DE69810906T2 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
WO2001057186A3 (en) Methods and compositions for diagnosis and treatment of cancer based on esf

Legal Events

Date Code Title Description
8364 No opposition during term of opposition